CD274 and neoplasm: Recently, a first-in-class immune-modulatory vaccine (IO102/IO103) against IDO and PD-L1 that targets immunosuppressive cells and tumor cells expressing IDO and/or PD-L1 has been applied in combination with nivolumab to treat patients with melanomas (NCT03047928).